Eli Lilly (LLY) vs. NVIDIA (NVDA)
This page compares Eli Lilly (LLY) with NVIDIA (NVDA) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas NVIDIA (NVDA) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.
| Symbol | LLY | NVDA |
|---|---|---|
| Name | Eli Lilly and Company | NVIDIA Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Semiconductors & Semiconductor Equipment |
| GICS Industry | Pharmaceuticals | Semiconductors & Semiconductor Equipment |
| GICS Sub-Industry | Pharmaceuticals | Semiconductors |
| Market Capitalization | 1,020.76 billion USD | 5,042.57 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | January 22, 1999 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
NVIDIA (NVDA) at 31.83 trades in the lower-multiple quartile for Price-to-Earnings Ratio (TTM), while Eli Lilly (LLY) at 40.65 sits around the industry midpoint — NVDA has a lower trailing earnings multiple relative to peers, though the gap should be read alongside growth and earnings quality.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.65
- Max
- 86.12
- Q3
- 44.09
- Median
- 25.14
- Q1
- 14.77
- Min
- 1.59
NVDA
Semiconductors & Semiconductor Equipment industry group
31.83
- Max
- 249.03
- Q3
- 128.05
- Median
- 64.96
- Q1
- 44.86
- Min
- 6.63
Price-to-Sales Ratio (TTM)
On Price-to-Sales Ratio (TTM), both Eli Lilly (LLY) at 14.13 and NVIDIA (NVDA) at 19.89 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.13
- Max
- 41.86
- Q3
- 22.86
- Median
- 6.80
- Q1
- 3.35
- Min
- 0.01
NVDA
Semiconductors & Semiconductor Equipment industry group
19.89
- Max
- 37.59
- Q3
- 20.61
- Median
- 9.67
- Q1
- 4.25
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Both look rich against book: NVIDIA (NVDA) at 25.80 sits in the upper Price-to-Book Ratio (MRQ) quartile, and Eli Lilly (LLY) at 32.78 prices even higher, above its industry range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.78
- Max
- 12.97
- Q3
- 6.18
- Median
- 3.45
- Q1
- 1.62
- Min
- -4.60
NVDA
Semiconductors & Semiconductor Equipment industry group
25.80
- Max
- 25.80
- Q3
- 14.33
- Median
- 7.69
- Q1
- 3.77
- Min
- 0.22
Valuation at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 40.65 | 31.83 |
| Price-to-Sales Ratio (TTM) | 14.13 | 19.89 |
| Price-to-Book Ratio (MRQ) | 32.78 | 25.80 |
| Free Cash Flow Yield | 0.90% | 0.92% |
Profitability
Return on Equity (TTM)
Both Eli Lilly (LLY) at 107.46% and NVIDIA (NVDA) at 114.29% post Return on Equity (TTM) above their industry benchmark ranges, pointing to unusually strong headline returns on shareholders’ equity.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- Max
- 100.65%
- Q3
- 3.39%
- Median
- -31.16%
- Q1
- -61.60%
- Min
- -158.89%
NVDA
Semiconductors & Semiconductor Equipment industry group
114.29%
- Max
- 39.82%
- Q3
- 17.52%
- Median
- 6.57%
- Q1
- -4.94%
- Min
- -35.15%
Net Profit Margin (TTM)
Both Eli Lilly (LLY) at 34.99% and NVIDIA (NVDA) at 62.97% keep an unusually large share of revenue as bottom-line profit — each Net Profit Margin (TTM) clears its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- Max
- 13.81%
- Q3
- 4.07%
- Median
- 0.00%
- Q1
- -3.07%
- Min
- -13.58%
NVDA
Semiconductors & Semiconductor Equipment industry group
62.97%
- Max
- 57.72%
- Q3
- 20.98%
- Median
- 7.10%
- Q1
- -3.84%
- Min
- -32.92%
Operating Profit Margin (TTM)
Both Eli Lilly (LLY) at 49.39% and NVIDIA (NVDA) at 65.60% squeeze more operating profit from each sales dollar than most peers, ranking in the top Operating Profit Margin (TTM) quartile of their industries.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- Q3
- 4.94%
- Median
- 0.00%
- Q1
- -133.46%
- Min
- -337.81%
NVDA
Semiconductors & Semiconductor Equipment industry group
65.60%
- Max
- 65.60%
- Q3
- 21.58%
- Median
- 9.68%
- Q1
- -8.51%
- Min
- -46.64%
Profitability at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| Return on Equity (TTM) | 107.46% | 114.29% |
| Return on Assets (TTM) | 20.74% | 52.73% |
| Net Profit Margin (TTM) | 34.99% | 62.97% |
| Operating Profit Margin (TTM) | 49.39% | 65.60% |
| Gross Profit Margin (TTM) | 82.83% | 74.15% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| 1-Year Revenue Growth | 44.70% | 65.47% |
| 3-Year Revenue CAGR | 31.69% | 100.05% |
EPS Growth
EPS Growth at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| 1-Year EPS Growth | 95.99% | 66.67% |
| 3-Year EPS CAGR | 51.71% | 204.24% |
Financial Strength
Current Ratio (MRQ)
NVIDIA (NVDA) at 3.44 keeps Current Ratio (MRQ) within its industry mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.47
- Q1
- 2.69
- Min
- 0.23
NVDA
Semiconductors & Semiconductor Equipment industry group
3.44
- Max
- 11.30
- Q3
- 6.01
- Median
- 3.26
- Q1
- 2.37
- Min
- 0.51
Debt-to-Equity Ratio (MRQ)
NVIDIA (NVDA) at 0.07 carries Debt-to-Equity Ratio (MRQ) around its industry mid-range, while Eli Lilly (LLY) at 1.39 sits in the higher-leverage quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- Q3
- 0.69
- Median
- 0.16
- Q1
- 0.02
- Min
- 0.00
NVDA
Semiconductors & Semiconductor Equipment industry group
0.07
- Max
- 1.53
- Q3
- 0.64
- Median
- 0.21
- Q1
- 0.04
- Min
- 0.00
Financial Strength at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| Current Ratio (MRQ) | 1.50 | 3.44 |
| Debt-to-Equity Ratio (MRQ) | 1.39 | 0.07 |
| Net Debt / EBITDA | 1.05 | -0.24 |
Dividends
Dividend Yield (TTM)
NVIDIA (NVDA) at 0.48% reports Dividend Yield (TTM) in the top quartile of industry peers, ahead of Eli Lilly (LLY) at 0.60%, which sits around the industry mid-range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.60%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVDA
Semiconductors & Semiconductor Equipment industry group
0.48%
- Max
- 1.15%
- Q3
- 0.46%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
NVIDIA (NVDA) at 0.61% maintains Dividend Payout Ratio (TTM) around its industry median — a balanced dividend policy. Eli Lilly (LLY) at 22.13% sits outside the typical mid-range, leaning toward more retention or more distribution than the industry median.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NVDA
Semiconductors & Semiconductor Equipment industry group
0.61%
- Max
- 41.26%
- Q3
- 19.10%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| Dividend Yield (TTM) | 0.60% | 0.48% |
| Dividend Payout Ratio (TTM) | 22.13% | 0.61% |
Performance & Risk
NVIDIA (NVDA) has a highly aggressive beta of 2.20, indicating much higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.51 and tends to be less market-sensitive — a wide gap in beta profiles.
Performance & Risk at a Glance
| Symbol | LLY | NVDA |
|---|---|---|
| 1-Year Return | 50.32% | 47.43% |
| 1-Year Volatility | 38.24% | 34.88% |
| Beta | 0.51 | 2.20 |
| 3-Month Avg. Volume | 3.15M | 165.98M |